Improved lung-thorax compliance in the premature rabbit neonate after treatment with dibuturyladenosine-3':5'-cyclic monophosphate

Acta Obstet Gynecol Scand. 1984;63(6):523-5. doi: 10.3109/00016348409156713.

Abstract

Premature rabbit neonates, delivered on day 28 of gestation, were treated with a single dose of dibuturyladenosine-3':5'-cyclic monophosphate (cyclic AMP), 300 mg/kg, immediately after delivery, saline-injected litter-mates serving as controls. All animals were kept in body plethysmographs and ventilated artificially with 100% oxygen for 1 h, with a maximal tidal volume of 10 ml/kg body weight. Lung-thorax compliance was significantly improved in animals treated with cyclic AMP, both 30 and 60 min after onset of ventilation (0.92 +/- 0.09 vs. 0.59 +/- 0.08 ml/cm H2O.kg and 0.96 +/- 0.09 vs. 0.53 +/- 0.08, p less than 0.005), but there was no improvement in alveolar air expansion, evaluated histologically. Phosphatidylglycerol was absent in alveolar wash from all control animals, but present in 3 of the 8 pooled samples from the animals treated with cyclic AMP; this difference was not statistically significant, however.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Newborn / physiology*
  • Bucladesine / pharmacology*
  • Gestational Age
  • Lung / pathology
  • Lung Compliance / drug effects*
  • Organ Size
  • Phospholipids / metabolism
  • Pulmonary Alveoli / metabolism
  • Rabbits
  • Respiration, Artificial

Substances

  • Phospholipids
  • Bucladesine